Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30238% above fair value
$4.59−0.09 (-1.89%)
Close on Nov 17, 2026Market cap $63.91MP/E –Yield –
Champions Oncology pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Champions Oncology's pe ratio was 35.0× on Feb 27, 2026, against 465.0× a year earlier. Over the last 3 years it ranged from 13.3× to 977.0×, with a median of 250.0×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Feb 27, 2026 | 35.0× | −5.6 |
| 2025 | Dec 31, 2025 | 40.6× | −424.4 |
| 2023 | Feb 28, 2023 | 465.0× | +14.0 |
| 2022 | Dec 30, 2022 | 451.0× | +172.3 |
| 2021 | Dec 31, 2021 | 278.7× | −261.3 |
| 2019 | Aug 30, 2019 | 540.0× | – |
See a number that looks wrong?